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TrendsAim: To assess the temporal changes in the quality indicators pertaining to the process
measures of diabetes care during a recent decade in Japan.
Methods: A five-fold repeated cross-sectional study was conducted using health insurance
claims data provided by the Japan Medical Data Center between April 2006 and March 2016.
We identified 46,631 outpatients with antidiabetic medication who regularly visited hospi-
tals or clinics at least every three months. We evaluated the quality indicators pertaining to
glycemic control monitoring, lipid profile monitoring, retinopathy screening, nephropathy
screening, and appropriate medication choice. The proportions of patients who received
appropriate examinations/prescriptions, by observation period and either the type of
antidiabetic medication or facility type were estimated using generalized estimating equa-
tion (GEE) models with multiple covariate adjustments.
Results: The quality indicator values for appropriate medication choice and nephropathy
screening improved between 2007 and 2015, whereas those for glycemic control monitoring
and retinopathy screening remained suboptimal. Patients prescribed medications in larger
hospitals were likelier to undergo the recommended examinations (e.g. retinopathy screen-
ing: 36.1% (95% CI: 35.4–36.7%) for clinic, 40.6% (95% CI: 39.1–42.2%) for smaller hospital, and
46.0% (95% CI: 44.8–47.2%) for larger hospital in 2015).
Conclusions: Several process measures of diabetes care remained suboptimal in Japan.
 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The increasing prevalence of diabetes and the resulting eco-
nomic burden pose a great challenge to public health andhealthcare systems, worldwide [1]. The provision of a high
quality of care and regular physician consultations may
reduce the risk of microvascular and macrovascular compli-
cations and mortality [2–4]. Therefore, improving the qualityealth and
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cemic control and regular monitoring of the associated com-
plications, is vital.
According to Donabedian, the quality of healthcare can be
assessed based on structure, process, and outcomes [5]. The
quality of diabetes care is often measured through process
measures and intermediate outcome measures in addition
to outcome measures [6]. Process measures (quality indica-
tors on process aspects) include clinical practices such as gly-
cemic control monitoring, lipid profile monitoring,
retinopathy screening, nephropathy screening, and appropri-
ate medication choice. Clinical guidelines provide tools for
the evaluation of the process measures of diabetes care [7–
9]. Various studies in the United States (US) [10–13], European
countries [14–19], South Korea [20], and other countries [21,22]
have reported on the quality of diabetes care. Those studies
demonstrated the temporal improvements in the quality
measures observed; however, patients with diabetes received
lower-quality diabetes care in some healthcare settings, with
some previous studies demonstrating that patient character-
istics and the presence of comorbidities affect the quality of
diabetes care [23,24].
In Japan, where the prevalence rate of diabetes was 12.1%
(16.3% for men and 9.3% for women) among adults in 2016,
there is a need to improve the quality of diabetes care [25].
A few studies focusing on the quality of diabetes care have
been performed in Japan; while some of those studies indi-
cated the steady performance of glycemic control monitoring,
it was observed that retinopathy screening and nephropathy
screening were less frequently performed than the optimum
even under universal health coverage [26,27]. In addition,
our group previously reported that insulin prescription and
attending follow-ups in larger facilities were associated with
a higher quality of diabetes care [26]. However, as those stud-
ies were conducted separately, their findings are not neces-
sarily comparable; temporal changes in the quality of
diabetes care in Japan have not been documented in a com-
prehensive manner to date. Further study is necessary to gain
clarity on the progress in diabetes care through clinical devel-
opment initiatives (e.g. the Japanese Clinical Guideline for
diabetes care was firstly published in 2004, and since then
revised every three years.) [7].
In this context, the present study aimed to assess the tem-
poral changes in the quality indicators pertaining to the pro-
cess of diabetes care especially in terms of appropriate
examination and prescription, with consistent data and
design, during a recent decade in Japan.
2. Subjects, materials and methods
2.1. Research design
We conducted a five-fold repeated cross-sectional study using
health insurance claims data in Japan, collected and pro-
cessed by the Japan Medical Data Center (JMDC). The JMDC
Claims Database comprises a series of claims data from sev-
eral health insurance societies for employees of large compa-
nies and their families, collected securely under the contractbetween the JMDC and these societies. The collected data
were processed in terms of anonymization and code stan-
dardization [28]. The JMDC Claims Database began collecting
claims data in 2005 and the number of beneficiaries has
increased gradually in the past decade (248,552 beneficiaries
in 2005 and 2,448,581 beneficiaries in 2015). The validity of
claim-based patient identification using this database has
been reported with regard to diabetes, hypertension, and dys-
lipidemia [29].
We observed 10 fiscal years that were divided into five
periods; (1) April 2006 to March 2008, (2) April 2008 to March
2010, (3) April 2010 to March 2012, (4) April 2012 to March
2014, and (5) April 2014 to March 2016. In total, the JMDC
Claims Database contains data on 3,740,239 beneficiaries
(2,042,548 men and 1,697,691 women) who were covered by
health insurance societies between April 2006 and March
2016. For each 2-year period, we defined the former fiscal
year (April to March) as the subject-identification year, within
which we identified patients with antidiabetic medication
who had regularly visited hospitals or clinics. Subsequently,
we defined the latter fiscal year as the quality-reporting year,
within which we assessed quality indicators among outpa-
tients in whom follow-up visits were accomplished without
any hospitalization.
In the present study, we included patients aged 20–
69 years who had visited hospitals/clinics at least every three
months and used antidiabetic medication during the subject-
identification year. In our claims database, more than 95% of
oral hypoglycemic agents were prescribed for 90 days or less
per prescription. For the calculation of each quality indicator,
we excluded (1) those in whom regular hospitals/clinics visits
were not accomplished during the quality-reporting year and
(2) those who were hospitalized during the quality-reporting
year. In addition, we excluded (3) those whose medical prac-
tices may not have been captured by claims data due to the
comprehensive payment system. In addition, we excluded
patients in whom the examinations and/or prescriptions
were no longer recommended due to the presence of a partic-
ular comorbidity. Particularly with regards to [3], all detailed
criteria are described below. A flow diagram of patients’ iden-
tification is presented in Fig. 1 (see also Appendix 1 regarding
the RECORD statement) [30].
2.2. Identification of patients with antidiabetic medication
We identified patients with a diagnosis of diabetes based on
whether their claims data included the diagnosis of dia-
betes, as determined by International Statistical Classifica-
tion of Diseases and Related Health Problems 10th
Revision (ICD-10) codes E10-E14 during the subject-
identification year; we did not consider ‘‘suspected” dia-
betes as the presence of diabetes. We identified patients
with antidiabetic medication based on at least one prescrip-
tion during the subject-identification year. We finally identi-
fied patients with diabetes using a combination of the
diagnosis of diabetes and prescription of antidiabetic med-
ication to increase the specificity of case detection at the
expense of sensitivity [26,29].
Fig. 1 – Flow diagram of the identification of patients with antidiabetic medication.
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2.3.1. Patient characteristics
We categorized the patients’ ages into five groups: 20–29, 30–
39, 40–49, 50–59, and 60–69 years, by sex. As for the type of
diabetes, if patients had at least one diagnosis of insulin-
dependent diabetes mellitus (IDDM, ICD-10: E10) on medical
claim, we classified them as having a diagnosis of IDDM.
Among the remaining patients, those who had at least one
diagnosis of non-insulin dependent diabetes mellitus
(NIDDM), other types of diabetes, and diabetes type that
was unknown (ICD-10: E11-14) were classified as those with
a diagnosis of NIDDM or other types of diabetes (NIDDM/
others). We identified patients with hypertension (I10-15)
and those with a diagnosis of dyslipidemia (E78), except pure
hypertriglyceridemia, hyperchylomicronemia, and lipopro-
tein deficiency (E78.1, E78.3, and E78.6) during the quality-
reporting year.2.3.2. Types of antidiabetic medication
Insulin and/or GLP-1 analogues were defined by the pre-
scription of ‘‘A10C”, ‘‘A10D”, and ‘‘A10S” in the Anatomical
Therapeutic Chemical (ATC) Classification System managed
by the European Pharmaceutical Market Research Associa-
tion (Appendix 2) [31]. Oral hypoglycemic agents were
included as ‘‘A10H”, ‘‘A10J”, ‘‘A10K”, ‘‘A10L”, ‘‘A10M”,
‘‘A10N”, ‘‘A10P”, and ‘‘A10X” in the ATC Classification Sys-
tem. We excluded ‘‘Voglibose, 0.2 mg” (A10BF03) and ‘‘Epal-
restat” (A10XA) prescriptions because they were covered for
the prevention of type 2 diabetes and diabetic neuropathy,
respectively.
2.3.3. Medical facility in which antidiabetic medication was
prescribed
We also identified the medical facility in which the antidia-
betic medication was last prescribed for each patient in the
subject-identification year; we then grouped the facilities into
the following three categories: hospital with 200 beds (larger
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clinic (without beds or with fewer than 20 beds).
2.4. Dropout and hospitalization
We defined ‘‘dropout” as the absence of hospital/clinic visits
for three or more consecutive months during the quality-
reporting year. After dropout patients were excluded, we also
excluded those who had a history of admission during the
quality-reporting year based on the presence of hospitaliza-
tion in the claims data.
2.5. Quality indicators
2.5.1. Steady performance of recommended examinations
As for examinations, we measured the following aspects of
diabetes care: (1) glycemic control monitoring, (2) lipid profile
monitoring, (3) retinopathy screening, and (4) nephropathy
screening.
(1) For glycemic control monitoring, an HbA1c test at a
pace of 1 per three months was considered standard based
on the clinical guideline and previous studies [26,32]. (2) For
lipid profile monitoring, serum lipid tests (any three tests
from among total cholesterol, low-density lipoprotein choles-
terol, high-density lipoprotein cholesterol, and triglyceride
tests) conducted at least once a year were considered appro-
priate. (3) Annual eye examinations included one complete
fundus examination or more, pan-vitreoretinal examinations,
or the use of fundus cameras. (4) For nephropathy screening,
the performance of one or both of the following tests was
considered appropriate: urine protein quantitative test or
urine albumin quantitative test. For the urine protein test,
we excluded patients on dialysis and/or with a diagnosis of
end-stage renal disease, for whom these tests were no longer
recommended. In addition, the results of serum creatinine
tests in a year were assessed.
2.5.2. Appropriate medication choice for patients with
hyperlipidemia and/or hypertension
Statin use and the disease name of hyperlipidemia were iden-
tified for the assessment of appropriate statin prescription
among patients with hyperlipidemia. Statin prescription
was detected from the prescription of ‘‘C10A1” and ”C11A1”
in the ATC Classification System [31].
We also considered angiotensin-converting-enzyme (ACE)
inhibitor or angiotensin II receptor blocker (ARB) use among
patients with hypertension as appropriate. Antihypertensive
drugs were identified using the same drug list as that used
in a previous study [33]. ACE inhibitor or ARB prescription
was detected from the prescription of ‘‘C9A”, ‘‘C9B”, ‘‘C9C”,
and ‘‘C9D” in the ATC Classification System [31].
2.6. Statistical analysis
After we identified the patients with antidiabetic medication
in each subject-identification year, the sex-specific and age-
specific proportions of patients with diabetes were calculated.
We then computed the proportions of dropouts and hospital-
ization in the quality-reporting year. From this point forward,
those who dropped out, those who were hospitalized, andthose whose examinations/prescriptions may not have been
captured due to comprehensive payment were excluded,
although such caseswere an exception (the numbers aremen-
tioned elsewhere in the article). We calculated the proportion
of crude examinations/prescriptions and temporal changes
(P for trend).
In order to estimate quality indicators by patient and facil-
ity characteristics, we constructed generalized estimating
equation (GEE) models with the logit link function and an
exchangeable correlation structure with independent vari-
ables as follows. We used the type of antidiabetic medication
(insulin and/or GLP-1 analogue group or oral hypoglycemic
agent group) and type of medical facility (larger hospital,
smaller hospital, and clinic) as the main predictors. We
adjusted for age (10-year age interval), sex, type of antidia-
betic medication and facility. We also included the observa-
tion period (categorical) in the regression model to address
secular changes. In addition, in order to estimate the adjusted
percentages of the quality indicators, we included an interac-
tion term between the observation period (categorical) and
type of antidiabetic medication (categorical) in the model
(Model 1), and observation period and type of facility (Model
2). We did not include the variable of IDDM diagnosis in the
model to avoid multicollinearity with the type of antidiabetic
medication. Finally, using these models, we calculated the
adjusted percentages by antidiabetic medication and facility
type, respectively. Changes in the quality indicators were
assessed by comparing the values between the first and last
quality-reporting years (2007 and 2015). All GEE models
addressed the possibly underestimated variance of propor-
tions by including the same individual patients in different
observation periods by designating the personal identification
variable as a cluster. We used Stata version 15.0 (Stata Corp,
College Station, TX, USA) for the statistical analysis and data
management. A p value lower than 0.05 was considered sta-
tistically significant.
Additional methodology information, for the definition of
patients with diabetes and quality indicator assessment, is
provided in supplementary file (Appendix 3).
3. Results
3.1. Patient characteristics
Table 1 shows the patients’ characteristics. The proportions of
patients with antidiabetic medication among all beneficiaries
aged 60–69 years were 11.5% for men and 7.4% for women in
April 2014. The average age had increased during the decade
(49.6 to 53.0 in men, 52.7 to 54.1 in women, 2006–2014). The
percentages of patients in whom the antidiabetic medication
prescribed was insulin and/or GLP-1 analogues plateaued at
approximately 19%. In 2014, 66.9% of patients with antidia-
betic medications received their prescriptions at clinics.
3.2. Dropout and hospitalization
While approximately 5–6% of the patients had dropped out,
about 10%were hospitalized in the quality-reporting year dur-
ing each study period (Table 1). These trends were stable dur-
ing this observation period. After the exclusion of those who
Table 1 – Patients’ characteristics in each observation period$ and number of dropouts and hospitalizations in the quality-reporting year.
April 2006 to March 2008 April 2008 to March 2010 April 2010 to March 2012 April 2012 to March 2014 April 2014 to March 2016 v2 test (P value)
Number of
patients (%)
Proportion of
patients*
Number of
patients (%)
Proportion of
patients*
Number of
patients (%)
Proportion of
patients*
Number of
patients (%)
Proportion of
patients*
Number of
patients (%)
Proportion
of patients*
Total
Observed patients 2266 1.0 3638 1.1 9991 1.2 17,705 1.4 38,105 1.7
Patients characteristics
Age (years old)
Men
Average age, Mean ± SD 49.6 ± 8.32 50.9 ± 8.58 51.4 ± 8.38 51.9 ± 8.35 53.0 ± 8.34
Total 1567 1.5 2569 1.8 7120 2.0 12,921 2.5 28,050 3.0
20–29 24 (1.5) 0.1 29 (1.1) 0.1 73 (1.0) 0.1 134 (1.0) 0.1 261 (0.9) 0.1
30–39 193 (12.3) 0.6 231 (9.0) 0.5 583 (8.2) 0.6 880 (6.8) 0.6 1441 (5.1) 0.6
40–49 459 (29.3) 1.8 769 (29.9) 2.0 2069 (29.1) 2.1 3749 (29.0) 2.5 7051 (25.1) 2.6 <0.01
50–59 799 (51.0) 4.9 1202 (46.8) 5.2 3166 (44.5) 5.5 5592 (43.3) 6.2 12,565 (44.8) 6.7
60–69 92 (5.9) 6.8 338 (13.2) 8.1 1229 (17.3) 8.6 2566 (19.9) 10.5 6732 (24.0) 11.5
Women
Average age, Mean ± SD 52.7 ± 9.61 52.5 ± 9.65 53.1 ± 9.59 53.3 ± 9.50 54.1 ± 9.24
Total 699 1.1 1069 1.2 2871 1.2 4784 1.3 10,055 1.6
20–29 8 (0.5) 0.1 13 (0.5) 0.1 46 (0.6) 0.1 79 (0.6) 0.1 134 (0.5) 0.1
30–39 67 (4.3) 0.3 115 (4.5) 0.4 230 (3.2) 0.3 343 (2.7) 0.3 541 (1.9) 0.3
40–49 146 (9.3) 0.9 231 (9.0) 0.9 652 (9.2) 0.9 1130 (8.7) 1.0 2232 (8.0) 1.1 <0.01
50–59 316 (20.2) 3.4 477 (18.6) 3.4 1148 (16.1) 3.0 1835 (14.2) 3.2 3936 (14.0) 3.2
60–69 162 (10.3) 8.7 233 (9.1) 6.3 795 (11.2) 7.0 1397 (10.8) 7.4 3212 (11.5) 7.4
Type of diabetes
Insulin dependent diabetes (E10) 125 (5.5) 176 (4.8) 483 (4.8) 756 (4.3) 1524 (4.0) <0.01
Non-insulin dependent diabetes and others (E11-14) 2141 (94.5) 3462 (95.2) 9508 (95.2) 16,949 (95.7) 36,581 (96.0)
Comorbid conditions (ICD-10)
Hyperlipidemia (E78, excluding hypertriglyceridemia
or other conditions for which statin is not applied)
1290 (56.9) 2309 (63.5) 6601 (66.1) 12,006 (67.8) 26,481 (69.5) <0.01
Hypertension (I10-15) 1047 (46.2) 1874 (51.5) 5575 (55.8) 10,301 (58.2) 22,868 (60.0) <0.01
Features of antidiabetic prescription
Type of antidiabetic medication
Insulin and/or GLP-1 analogue 445 (19.6) 722 (19.8) 1940 (19.4) 3239 (18.3) 6825 (17.9) <0.01
Oral antihyperglycemic agents only 1821 (80.4) 2916 (80.2) 8051 (80.6) 14,466 (81.7) 31,280 (82.1)
Type of medical facility
Hospital (=200 beds) 779 (34.4) 1052 (28.9) 2398 (24.0) 4059 (22.9) 8114 (21.3) <0.01
Hospital (20–199 beds) 187 (8.3) 354 (9.7) 1028 (10.3) 1734 (9.8) 4480 (11.8)
Clinic (0–19 beds) 1300 (57.4) 2232 (61.4) 6565 (65.7) 11,912 (67.3) 25,511 (66.9)
Dropouts and hospitalizations
in the quality-reporting year
Dropouts 141 (6.2) 204 (5.6) 490 (4.9) 892 (5.0) 1882 (4.9) 0.04
Hospitalization† 217 (10.2) 374 (10.9) 970 (10.2) 1591 (9.5) 3752 (10.4) 0.01
SD, standard deviation.
ICD-10: International Statistical Classification of Diseases and Related Health Problems, 10th Revision.
$ All patients had regularly visited clinics or hospitals at least every three months in the subject-identification year (the first fiscal year).
* Proportion of patients among all beneficiaries = (Number of patients with diabetic medication within the stratum)/(Number of all beneficiaries within the stratum) * 100.
† After dropout patients were excluded, we identified patients who had a history of admission during the quality-reporting year.
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tions of patients were 1908, 3060, 8531, 15,222, and 32,471 in
2007, 2009, 2011, 2013, and 2015, respectively.
3.3. Crude quality indicators
Table 2 shows the numbers of patients with antidiabetic med-
ication in whom the quality indicators during each study per-
iod and crude quality indicators in the quality-reporting year
were finally assessed. Patients whose examinations/prescrip-
tions may not have been captured due to comprehensive pay-
ment were excluded. For instance, 49, 56, 181, 318, and 685
patients were excluded due to comprehensive payment with
regards to the HbA1c test in 2007, 2009, 2011, 2013, and
2015, respectively. Regarding the urine protein test, 77
patients (in total) on dialysis and/or with a diagnosis of end-
stage renal disease were excluded, and all patients who
received their prescriptions in larger hospitals (200 beds)
were also excluded due to comprehensive payment.
The crude quality indicators were as follows: 68.2%
(n = 1859) and 68.9% (n = 31,786) for the HbA1c test (1 per
three months, P for trend < 0.01), and 42.0% (n = 1865) and
38.7% (n = 31,920) for eye examinations (P for trend < 0.01),
in 2007 and 2015, respectively. Regarding nephropathy screen-
ing, about 73% of the patients underwent any one of the urine
tests in the study period (P for trend = 0.51), but the propor-
tions of those who underwent a quantitative urine protein
test were 14.0% (n = 913) and 24.2% (n = 20,022) in 2007 and
2015, respectively (P for trend < 0.01).
3.4. Time trends in the quality indicators
3.4.1. Quality indicators by antidiabetic medication type
Fig. 2 shows the time trends in the quality indicators by
antidiabetic medication type after adjustment for covariates
(Model 1). The quality indicator values in the insulin and/or
GLP-1 analogue group were higher than those in the oral
hypoglycemic agent group (for instance, HbA1c test (1 per
three months), eye examinations, urine protein test, and
ACE inhibitor or ARB). Between 2007 and 2015, the proportion
of eye examinations was stable (insignificant changes), rang-
ing from 33.7% (95% CI: 31.6–35.7) in 2007 to 35.5% (95% CI:
34.9–36.0) in 2015 in the oral hypoglycemic agent group, and
57.2% (95% CI: 52.7–61.6) to 53.8% (95% CI: 52.6–55.1) in the
insulin and/or GLP-1 analogue group. The proportion of
patients who underwent a quantitative urine protein test
remained 22.2% (95% CI: 21.6–22.8) in the oral hypoglycemic
agent group and 39.1% (95% CI: 37.3–40.8) in the insulin and/
or GLP-1 analogue group in 2015. The differences in the pro-
portions between the prescription groups were eliminated
with regards to serum lipid tests and statin prescription
among the hyperlipidemia cases in 2015. Regarding ACE inhi-
bitor or ARB prescription, the proportions of patients in the
insulin and/or GLP-1 analogue group were significantly higher
than those of patients in the oral hypoglycemic agent group
during 2007–2015.
3.4.2. Quality indicators by the type of medical facility
Fig. 3 shows the time trends in the quality indicators by the
type of medical facility after adjustment for covariates (Model2). The quality indicator values in the larger hospital group
were generally higher than that in the clinic group, with the
value for the smaller hospital group positioned in the middle
in most cases. The proportions of patients who received an
HbA1c test (1 per three months) was 75.7% (95% CI: 74.2–
76.3) in the larger hospital group and 77.3% (95% CI: 76.0–
78.6) in the smaller hospital group, but remained at 65.8%
(95% CI: 65.2–66.4) in the clinic group in 2015. A comparison
of the proportions between 2007 and 2015 showed no or sub-
optimal improvement in the condition of patients with antidi-
abetic medication who were receiving annual eye
examinations: with values ranging from 47.6% (95% CI: 44.3–
51.0) to 46.0% (95% CI: 44.8–47.2) in the larger hospital group
and from 34.9% (95% CI: 32.5–37.4) to 36.1% (95% CI: 35.4–
36.7) in the clinic group; however, the value significantly
increased from 32.2% (95% CI: 25.5–38.9) to 40.6% (95% CI:
39.1–42.2) in the smaller hospital group. The proportions of
those who underwent a quantitative urine protein test did
not increase significantly, ranging from 20.4% (95% CI: 15.2–
25.6) in 2007 to 26.0% (95% CI: 24.5–27.4) in 2015 in the smaller
hospital group, but significantly increased from 13.9% (95% CI:
12.1–15.7) to 24.0% (95% CI: 23.4–24.6) in the clinic group. A sig-
nificant increase was observed in the proportions of patients
who received a statin prescription: from 59.6% (95% CI: 56.3–
62.8) in 2007 to 67.3% (95% CI: 66.1–68.6) in 2015 in the larger
hospital group, from 53.8% (95% CI: 46.8–60.7) to 64.1% (95%
CI: 62.4–65.9) in the smaller hospital group, and from 58.6%
(95% CI: 56.2–61.1) to 62.1% (95% CI: 61.4–62.8) in the clinic
group.
4. Discussion
4.1. Main findings
This study identified several important issues pertaining to
diabetes care in Japan in the period between 2007 and 2015.
First, although the quality indicators for lipid profile monitor-
ing, nephropathy screening, and medication choice among
Japanese patients with antidiabetic medications substantially
but incrementally improved over the decade, there were no
significant changes in the indicators for glycemic control
monitoring and retinopathy screening in the observed period.
Our findings, therefore, suggest that while the quality indica-
tors for the process of diabetes care were still suboptimal in
Japan, the medication choice practices for patients with
hyperlipidemia and/or hypertension had substantially
improved. Second, with regards to patient characteristics,
those treated with insulin and/or GLP-1 analogues had a
higher chance of receiving a better quality of care than those
treated with oral hypoglycemic agents. We also observed
higher quality indicator values among patients who were pre-
scribed antidiabetic medications at larger hospitals than
among those who received their prescription at clinics in
most cases. These results may provide useful benchmarks
for the improvement of the quality of diabetes care in Japan.
4.2. Interpretation
The proportions of indicators on both annual nephropathy
and retinopathy screening were still lower than those of the
Table 2 – Crude quality indicators in the quality-reporting year: fiscal year (April to March) (%).
2007 2009 2011 2013 2015 P for trend
(n = 1908) (n = 3060) (n = 8531) (n = 15,222) (n = 32,471)
Glycemic control monitoring
(n = observed patients)* (n = 1859) (n = 3004) (n = 8350) (n = 14,904) (n = 31,786)
HbA1c test (1 per year) 93.7 95.5 95.8 95.8 95.9 0.16
HbA1c test (1 per three months) 68.2 69.3 69.2 68.3 68.9 <0.01
Lipid profile monitoring
(n = observed patients)* (n = 1856) (n = 2990) (n = 8322) (n = 14,846) (n = 31,293)
Serum lipid test (1 per year) 75.5 83.3 84.9 84.9 85.4 <0.01
Retinopathy screening
(n = observed patients)* (n = 1865) (n = 3018) (n = 8384) (n = 14,960) (n = 31,920)
Eye examinations (1 per year) 42.0 40.3 38.5 37.8 38.7 <0.01
Nephropathy screening
(n = observed patients without dialysis and/or with
diagnosis of end-stage renal disease)*
(n = 913) (n = 1622) (n = 5082) (n = 9137) (n = 20,022)
Urine test (1 per year) 74.5 72.3 74.4 72.2 72.6 0.51
Urine protein test*,– (1 per year) 14.0 20.3 21.5 23.3 24.2 <0.01
(n = observed patients)* (n = 1855) (n = 2989) (n = 8319) (n = 14,833) (n = 31,260)
Serum creatinine test (1 per year) 88.0 88.2 88.2 88.3 88.6 <0.01
Appropriate medication choice
(n = observed patients)* (n = 1867) (n = 3022) (n = 8417) (n = 15,010) (n = 32,052)
Statin prescription 37.5 43.0 44.3 45.8 45.6 <0.01
ACE inhibitor or ARB prescription 34.1 38.4 43.5 45.6 45.4 <0.01
(n = observed patients with hyperlipidemia§)* (n = 1077) (n = 1917) (n = 5585) (n = 10,204) (n = 22,302)
Statin prescription 61.7 64.3 64.5 65.0 64.1 <0.01
(n = observed patients with hypertension and prescription of hypertensive drug)* (n = 768) (n = 1382) (n = 4234) (n = 7924) (n = 17,281)
ACE inhibitor or ARB prescription 77.0 78.9 82.5 83.6 82.0 <0.01
HbA1c; Glycated hemoglobin I, ACE; angiotensin-converting-enzyme; ARB, angiotensin II receptor blocker.
* Number of patients with diabetes in whom the quality indicator values were finally assessed.
– Any one or more urine protein test or urine albumin excretion tests.
§ Hyperlipidemia (excluding hypertriglyceridemia or other conditions for which statin is not applied).
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Fig. 2 – Changes in the adjusted percentage of quality indicators by the type of antidiabetic medication (Model 1).
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[26,27]. The proportion of patients who underwent nephropa-
thy screening at least once a year (microalbuminuria test) was
59.4% in European countries [14]. Compared to the propor-
tions of those who underwent any urine test including a urine
qualitative test (about 73%, with an insignificant change dur-
ing the period), the proportions of those who underwent a
urine quantitative protein test were quite small. This finding
implies that severe nephropathy may be detected well
through urine qualitative tests; however, early nephropathymay not be detected sufficiently due to the lack of a urine
quantitative protein test [7]. The quality indicator for
retinopathy screening was less optimal than those observed
in European countries and the US. For instance, 74.8% and
73.4% of patients with diabetes underwent retinopathy
screening in European countries and the US, respectively
[10,14]. We suspect that these suboptimal qualities pertain
to the physician’s attitude, payment systems, and the lack
of patients’ literacy on diabetes care; however, unfortunately,
our analysis could not identify the factors that prevent
Fig. 3 – Changes in the adjusted percentage of quality indicators by the type of medical facility in which antidiabetic
medication was prescribed (Model 2).
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ther study is required to understand why the quality of dia-
betes care in Japan has not improved sufficiently and is
lower than that in the US and European countries.
The result of the present study indicated that the values of
the quality indicators, especially those pertaining to glycemiccontrol monitoring and retinopathy screening, were higher
among patients using insulin and/or GLP-1 analogues and
those who were cared for at a larger medical facility. Together
with the suboptimal performances observedworldwide, these
differences may be induced by both ‘‘patient factors” and
‘‘provider factors” [34]. In terms of patient factors, patients
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(e.g., older patients) are likelier to be prescribed insulin; in
these patients, glycemic control and complications may be
assessed more intensively in order to titrate prescriptions in
response to blood glucose levels and to treat newly detected
lesions [35]. As for provider factors, the proportion of special-
ists (e.g., board-certified diabetologists) who are likely to pro-
vide better care for diabetes patients may be higher in larger
hospitals [36]. Future studies using datasets with more
detailed patient and provider information (e.g., duration of
diabetes and distribution of board-certified diabetologists)
may enable the investigation of the aforementioned hypo-
thetical relationship.
Even though patient and provider factors are associated
with quality indicators, initiatives should be taken to achieve
high adherence to the recommended quality of care regardless
of the characteristics of patients, physicians, and facilities. For
instance, at the facility level, medical facilities with accredita-
tion fromorganizations such as the Joint Commission Interna-
tional and the Japan Council for Quality Health Care are
expected to implement quality management continuously
[37,38]; the inclusion of quality indicators for diabetes care as
required items may help improve the quality of diabetes care
amongaccredited facilities and facilities seekingaccreditation.
Another potentially effective strategy could be incentivization
through the payment system. In the United Kingdom, physi-
cians are financially incentivized to provide a high quality of
care for patients with diabetes in the primary care setting
through the Quality and Outcomes Framework [15]. In Japan,
although the pay-for-performance framework has not been
introduced in the unit of physicians, incentives for quality
improvement per facility have already been introduced
through the centralized medical fee decision system and
nationwide universal health care coverage [39]. From another
viewpoint, the implementation of a regular fee-for-service
framework may also work in improving the quality of care in
Japanese healthcare settings. For instance, the exchange of
patients’ medical information between physicians and oph-
thalmologists via special notebooks called ‘‘Diabetes Collabo-
ration Notebook” or ‘‘Diabetes Eye Notebook”, which may
also function as personal health records, is widely followed in
Japan; the process of referral using these notebooks should be
reimbursed as proof of a better process of care.
We found that the medication choice for patients with
hyperlipidemia and/or hypertension had improved in the
study period, whereas unfavorable signs in the progress of
diabetes care were noted. This favorable trend could be attrib-
uted to improvements in the adherence to clinical guidelines
among Japanese physicians. However, the proportion of statin
prescriptions was still lower than 70% in 2015. Further
improvements are necessary to ensure appropriate lipid con-
trol, so as to prevent hyperlipidemia.
4.3. Strengths and limitations
To the best of our knowledge, it is the first study to investigate
the temporal changes in diabetes care in Japan. In order to
assess the quality indicator values among those in whom dia-
betes care was a requirement and those in whom the diabetes
care was assessable, we carefully identified patients withantidiabetic medication. We also successfully excluded those
who dropped out and/or were hospitalized during the obser-
vation period. Therefore, we believe that our study provides
a meaningful assessment of the recent changes in the dia-
betes care system in Japan. Moreover, the analytical methods
we employed, and the following discussion based on the anal-
yses can be generalizable to any medical system as long as it
collects and tabulates healthcare claims data.
The present study has several limitations. First, our study
population predominantly included patients with a relatively
high socioeconomic status, aged 20–69 years; therefore, the
quality of care for elderly patients was beyond the scope of
the study. Second, we could not collect data on individual
patients’ test results (e.g., HbA1c level), because medical
claims do not contain clinical test results. Data including both
claims and individual test results may facilitate the investiga-
tion of the relationship between process and outcome mea-
sures with regards to diabetes care. Third, our analysis
allowed for patients to be included in several study periods.
This may have distorted our analysis in terms of the effi-
ciency of the prediction of the quality indicators; however,
we dealt with this problem using cluster terms (patients) in
the GEE model. Fourth, differences in patients’ characteristics
(e.g. average age, types of medical facility where prescribed,
and dropouts/hospitalization rates) existed across the five
study periods along with substantial changes in the numbers
of study participants (Table 1). Although we compensated for
the limitation by statistical modelling, residual confounding
that can distort our trend analysis, may still remain. There-
fore, data shown in Table 2, Figs. 2 and 3 should be interpreted
with careful insight.
4.4. Conclusion
The quality of diabetes care was overall still suboptimal in
Japan as of 2015, especially with regards to diabetic nephropa-
thy and retinopathy screening. However, we observed an
improvement in the medication choice for patients with
hyperlipidemia and/or hypertension, implying that an
increasing number of Japanese physicians are starting to fol-
low clinical guidelines. Future measures in improving dia-
betes care in Japan should focus both on improving overall
quality and reducing quality gaps.
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